Therapeutic Workshop
Cancer Genome Project, Part I: Implications for Sequencing Technology
Thursday, October 20
3:30 p.m. - 4:30 p.m.
Sea Cliff
The goal of the Human Cancer Genome Project is to obtain a comprehensive description of the genetic basis of cancer. Through an exploration of sequencing and re-sequencing the NIH seeks to better understand the disease initiation, progression, response to therapy, and importance in disease diagnosis. As contemplated, this 10-year, $1.5 billion effort would profile 50 tumor types, each in 250 individuals. This comprehensive knowledge of the genetic basis of cancer would provide a permanent foundation for all future cancer research and would have far-reaching implications for the creation of new diagnostics and therapeutics. The NCI and NHGRI have jointly committed a total of $100 million in a pilot project to begin in 2006. This panel brought together academic and industry experts to discuss the Human Cancer Genome Project and its implications for technology and therapeutic industry participants.
Moderator:
- Geoffrey Duyk, MD, PhD, Managing Director, TPG Ventures, Inc.
Panelists:
- Kevin Corcoran, Vice President and General Manager, Genetic Analysis, Applied Biosystems
- Richard A. Gibbs, PhD, Director and Wofford Cain Endowed Chair, Human Genome Sequencing Center, Baylor College of Medicine
- Christopher K. McLeod, President & CEO, 454 Life Sciences Corporation
- John S. West, Chief Executive Officer, Solexa, Inc.